N

NextCure Inc
NASDAQ:NXTC

Watchlist Manager
NextCure Inc
NASDAQ:NXTC
Watchlist
Price: 11.39 USD
Market Cap: 30.5m USD

Relative Value

There is not enough data to reliably calculate the relative value of NXTC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NXTC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.7
Industry
23.7
Forward
-0.7
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.9
Industry
22
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.9
Industry
23.8
vs History
3
vs Industry
75
Median 3Y
0.3
Median 5Y
0.5
Industry
3.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
19
Median 3Y
0.9
Median 5Y
0.9
Industry
6.4
vs History
vs Industry
17
Median 3Y
0.8
Median 5Y
0.8
Industry
7
Forward
-0
vs History
vs Industry
20
Median 3Y
1.1
Median 5Y
1.1
Industry
8.3
vs History
vs Industry
15
Median 3Y
1.1
Median 5Y
1
Industry
6.5
vs History
9
vs Industry
Median 3Y
-4.2
Median 5Y
-3.7
Industry
5.7

Multiples Across Competitors

NXTC Competitors Multiples
NextCure Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
NextCure Inc
NASDAQ:NXTC
30.4m USD 0 -0.5 -0 -0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 794 036.5 -160 618 -195 041.5 -192 815.9
US
Abbvie Inc
NYSE:ABBV
392.9B USD 6.6 167.5 16.2 23
US
Amgen Inc
NASDAQ:AMGN
170.1B USD 4.7 24.3 17.6 17.6
US
Gilead Sciences Inc
NASDAQ:GILD
150.9B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.5B USD 9.8 31.1 22.8 23.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 084.7 -531.9 -579.2 -563.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.6B USD 5.5 17 16.1 18.3
AU
CSL Ltd
ASX:CSL
89.1B AUD 3.8 19.8 13.3 16.5
NL
argenx SE
XBRU:ARGX
46B EUR 15 35.3 61 62.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.8B USD 16.1 1 188.8 156.1 189.3
P/S Multiple
Revenue Growth P/S to Growth
US
N
NextCure Inc
NASDAQ:NXTC
Average P/S: 3 379 618.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 794 036.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 084.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.1
46%
0.4
P/E Multiple
Earnings Growth PEG
US
N
NextCure Inc
NASDAQ:NXTC
Average P/E: 187.8
Negative Multiple: -0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 618 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.5
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
9%
1.9
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
35.3
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 188.8
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
N
NextCure Inc
NASDAQ:NXTC
Average EV/EBITDA: 39.5
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 041.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.6
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
11%
1.5
AU
CSL Ltd
ASX:CSL
13.3
8%
1.7
NL
argenx SE
XBRU:ARGX
61
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
156.1
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
N
NextCure Inc
NASDAQ:NXTC
Average EV/EBIT: 45.5
Negative Multiple: -0
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 815.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.6
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.3
13%
1.4
AU
CSL Ltd
ASX:CSL
16.5
11%
1.5
NL
argenx SE
XBRU:ARGX
62.6
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
189.3
N/A N/A